For help on how to get the results you want, see our search tips.
2 results
Medicine
Maximum residue limits Remove Maximum residue limits filter
Referrals Remove Referrals filter
Orphan designations Remove Orphan designations filter
Referral authorisation model
Centrally authorised product(s) Remove Centrally authorised product(s) filter
Referral decision making model
PRAC-CHMP-EC Remove PRAC-CHMP-EC filter
Referral PRAC recommendation
Risk minimisation measures Remove Risk minimisation measures filter
Referral safety status
Yes Remove Yes filter
-
List item
Referral: Janus kinase inhibitors (JAKi)
tofacitinib, abrocitinib, baricitinib, upadacitinib, filgotinib, associated names: Xeljanz, Cibinqo, Olumiant, Rinvoq, Jyseleca, Article 20 procedures
Status: European Commission final decision, opinion/position date: 23/01/2023, EC decision date: 10/03/2023, Last updated: 22/05/2023 -
List item
Referral: Lemtrada
alemtuzumab, associated names: Lemtrada, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 16/01/2020, Last updated: 04/02/2020